Natriumoxybat Kalceks (Sodium Oxybate)

Sodium oxybate acts as an agonist at GABA_B receptors in the brain, enhancing inhibitory neurotransmission. This action promotes slow‑wave (deep) sleep, stabilizes sleep architecture, and consequently diminishes cataplexy and excessive daytime sleepiness in people with narcolepsy.

The dosage of sodium oxybate is individualized and set by the prescribing clinician based on the patient’s clinical response, tolerability, and any relevant medical conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sodium oxybate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made together with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Sodium oxybate is the only medication approved specifically for cataplexy and for improving nighttime sleep in narcolepsy. Other agents, such as modafinil or armodafinil, primarily address daytime sleepiness but do not treat cataplexy. Sodium oxybate’s unique GABA_B agonist profile offers a distinct therapeutic option.

Store Natriumoxybat Kalceks at ambient temperature, preferably below 25 °C. Keep the oral solution in its original container, protect it from moisture and direct light, and ensure the cap is tightly closed when not in use.

The product is supplied as an oral solution that is taken by mouth. The prescriber will provide specific instructions regarding the timing and volume of each dose, which is usually divided into two nightly administrations.

The most serious risks include respiratory depression, severe hypotension, seizures, and potentially life‑threatening allergic reactions. Patients should be monitored closely, especially when initiating therapy or when combined with other central nervous system depressants.

Sodium oxybate should be avoided in individuals with known hypersensitivity to the drug, severe respiratory disorders, uncontrolled sleep‑related breathing problems, or in patients who are concurrently using alcohol or other strong CNS depressants without medical supervision.